VYNE Therapeutics Inc.
VYNE | NASDAQ
$28.56
$0.00 (0.00%)
At close: Jul 27, 2026, 04:00 PM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
Revenue | 570K | 501K | 424K | 477K | 931K | 20.99M |
Cost of Revenue | 23K | n/a | n/a | n/a | n/a | 1.39M |
Gross Profit | 547K | 501K | 424K | 477K | 931K | 19.6M |
Operating Income | -29.75M | -43.64M | -29.26M | -34.3M | -38.91M | 252.55M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -26.73M | -39.8M | -27.87M | -33.93M | -43.76M | -255.83M |
Net Income | -26.48M | -39.83M | -28.45M | -23.21M | -73.33M | -255.57M |
Selling & General & Admin | 11.08M | 13.19M | 13.38M | 16.39M | 20.3M | 89.54M |
Research & Development | 19.24M | 30.95M | 16.31M | 18.39M | 19.54M | 43.53M |
Other Expenses | -23K | n/a | n/a | n/a | n/a | -366.02M |
Operating Expenses | 30.3M | 44.14M | 29.68M | 34.77M | 39.84M | -232.95M |
Interest Expense | n/a | n/a | n/a | n/a | 5.61M | 4.39M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 30.32M | 44.14M | 29.68M | 34.77M | 39.84M | -231.55M |
Income Tax Expense | 4K | 4K | n/a | 13K | 448K | -258K |
Shares Outstanding (Basic) | 855.36K | 851.78K | 205.46K | 63.72K | 57.18K | 36.02K |
Shares Outstanding (Diluted) | 855.36K | 851.78K | 205.46K | 63.72K | 57.18K | 36.02K |
EPS (Basic) | -31 | -47 | -138.50 | -532.50 | -1.28K | -7.1K |
EPS (Diluted) | -31 | -47 | -138.50 | -532.50 | -1.28K | -7.1K |
EBITDA | -26.73M | -39.8M | -27.87M | -33.86M | -38.04M | -251.1M |
EBIT | -26.73M | -39.8M | -27.87M | -33.93M | -38.15M | -251.44M |
Depreciation & Amortization | n/a | 4K | n/a | 72K | 109K | 341K |
Add to Watchlist
Select watchlists to add or remove VYNE